Two years into the pandemic, pharmaceutical firms remain a top target for cybercriminals, and that trend will undoubtedly persist in 2022, says Paul Prudhomme, a former Department of Defense threat analyst who is now a researcher with cybersecurity threat intelligence firm IntSights.